Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total value of $1,128,000.00. Following the completion of the transaction, the chief operating officer now directly owns 732,294 shares of the company’s stock, valued at $8,260,276.32. This represents a 12.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Eric Venker also recently made the following trade(s):

• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The stock was sold at an average price of $11.54, for a total value of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.49, for a total value of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00.

Roivant Sciences Stock Performance

ROIV stock opened at $11.21 on Friday. The stock’s 50 day simple moving average is $11.75 and its 200 day simple moving average is $11.60. Roivant Sciences Ltd. has a fifty-two week low of $9.69 and a fifty-two week high of $13.06. The company has a market cap of $8.16 billion, a P/E ratio of 1.98 and a beta of 1.27.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ROIV. Mutual of America Capital Management LLC raised its stake in shares of Roivant Sciences by 0.4% in the second quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock worth $3,457,000 after purchasing an additional 1,142 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after acquiring an additional 1,288 shares in the last quarter. Covestor Ltd grew its holdings in shares of Roivant Sciences by 9.1% in the third quarter. Covestor Ltd now owns 19,190 shares of the company’s stock valued at $222,000 after acquiring an additional 1,605 shares in the last quarter. US Bancorp DE grew its holdings in shares of Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after acquiring an additional 1,948 shares in the last quarter. Finally, Quarry LP grew its holdings in Roivant Sciences by 50.0% during the third quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after purchasing an additional 2,500 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.